Effects of PCSK-9 Inhibition by Alirocumab Treatments on Biliary Cirrhotic Rats
Sign Up to like & getrecommendations! Published in 2022 at "International Journal of Molecular Sciences"
DOI: 10.3390/ijms23137378
Abstract: Hyperlipidemia and oxidative stress with elevated oxidized low-density lipoprotein (ox-LDL) exacerbate hepatic inflammation and fibrosis. The plasma level of low-density lipoprotein (LDL) is controlled by proprotein convertase subtilisin/kexin 9 (PCSK9). Alirocumab is a monoclonal antibody… read more here.
Keywords: biliary cirrhotic; cirrhotic rats; oxidative stress; inhibition alirocumab ... See more keywords